Frontlight ResearchEarly access
Enrolling by invitationPhase 2
Long-term follow-up of people treated with genetically modified T cells
Follows people with blood cancers for up to 15 years after CAR T cell therapy.
Key facts
- Who runs it
- Autolus Limited
- Where
- Glasgow, London, Manchester, and Newcastle upon Tyne, United KingdomSee the 5 sitesAlso in 2 other countries, 4 sites
- Trial code
- Registry title
- Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 500 people, planned
- Started
- 2 Aug 2018
- Expected to end
- Dec 2043
- Type of study
- Interventional
- Treatments tested
- AUTO CAR T cell therapy
- Record updated
- 22 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received an AUTO CAR T cell therapy in a treatment study. They are followed for up to 15 years after their first infusion.
- Age
- 1 Year and older
- Sex
- All sexes can join.
- Earlier treatment
- Must have received an AUTO CAR T cell therapy in a clinical treatment study.
Main reasons for not taking part
- The record names no specific exclusion criteria.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients must have received an AUTO CAR T cell therapy on a clinical treatment study
- Patients must have provided informed consent for long-term follow-up study prior to participation
- Patients must be able to comply with the study requirements
Who cannot take part
- There are no specific exclusion criteria for this study
Where in United Kingdom
Also in 2 other countries, 4 sites
- Queen Elizabeth University HospitalGlasgow, United KingdomEnrolling by invitation
- University College London Hospitals NHS Foundation TrustLondon, United KingdomEnrolling by invitation
- Manchester Royal Infirmary HospitalManchester, United KingdomEnrolling by invitation
- Royal Manchester Children's HospitalManchester, United KingdomEnrolling by invitation
- Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, United KingdomEnrolling by invitation
About the trial
What the trial wants to find out
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
The group in the trial
- AUTO CAR T cell therapyTreatment being tested
Patients who received previous treatment with AUTO CAR T Cell Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors
- Plain-language title
- Long-term follow-up of people treated with genetically modified T cellsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 September 2026